Evidence map›Paper›PMID 38596313›Full record

ReviewComputational and structural biotechnology journal2024

The molecular subtypes of autoimmune diseases.

Xiangshu Cheng, Xin Meng, Rui Chen, Zerun Song, Shuai Li, Siyu Wei, Hongchao Lv, Shuhao Zhang, Hao Tang, Yongshuai Jiang and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Computational and structural biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Incorporating Real-World Variability in Clinical IBD Research.Journal of evaluation in clinical practice · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiangshu ChengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xin MengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Rui ChenCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Zerun SongCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Shuai LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Siyu WeiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Hongchao LvCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Shuhao ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Hao TangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yongshuai JiangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Ruijie ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases (ADs) are characterized by their complexity and a wide range of clinical differences. Despite patients presenting with similar symptoms and disease patterns, their reactions to treatments may vary. The current approach of personalized medicine, which relies on molecular data, is seen as an effective method to address the variability in these diseases. This review examined the pathologic classification of ADs, such as multiple sclerosis and lupus nephritis, over time. Acknowledging the limitations inherent in pathologic classification, the focus shifted to molecular classification to achieve a deeper insight into disease heterogeneity. The study outlined the established methods and findings from the molecular classification of ADs, categorizing systemic lupus erythematosus (SLE) into four subtypes, inflammatory bowel disease (IBD) into two, rheumatoid arthritis (RA) into three, and multiple sclerosis (MS) into a single subtype. It was observed that the high inflammation subtype of IBD, the RA inflammation subtype, and the MS "inflammation & EGF" subtype share similarities. These subtypes all display a consistent pattern of inflammation that is primarily driven by the activation of the JAK-STAT pathway, with the effective drugs being those that target this signaling pathway. Additionally, by identifying markers that are uniquely associated with the various subtypes within the same disease, the study was able to describe the differences between subtypes in detail. The findings are expected to contribute to the development of personalized treatment plans for patients and establish a strong basis for tailored approaches to treating autoimmune diseases.

Indexed as

Autoimmune diseasesDisease heterogeneityMolecular subtypePrecision medicine

Identifiers

PMID38596313
PMCPMC11001648
OpenAlexW4393282884

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.